Skip to main navigation
Skip to search
Skip to main content
Augusta University Research Profiles Home
Help & FAQ
Link opens in a new tab
Search content at Augusta University Research Profiles
Home
Profiles
Research Units
Scholarly Output
Projects
Datasets
Equipment
Activities
Press/Media
Prizes
Differential roles of uPAR in peritoneal ovarian carcinomatosis
Nada N. Al-Hassan
, Ali Behzadian
, Ruth Caldwell
, Vessela S. Ivanova
, Viqar Syed
, Kouros Motamed
, Neveen A. Said
Cellular Biology and Anatomy
Research output
:
Contribution to journal
›
Article
›
peer-review
32
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Differential roles of uPAR in peritoneal ovarian carcinomatosis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
100%
Ovarian Carcinomatosis
100%
Ovarian Cancer
38%
Tumor
15%
Ascitic Fluid
15%
Peritoneal Implants
15%
United States
7%
Tumor Cells
7%
Solid Tumors
7%
Mechanistic Studies
7%
Surgical Debulking
7%
Epithelial Ovarian Cancer
7%
Ablation
7%
Tumor Mass
7%
Patient Survival
7%
Survival Rate
7%
Macrophage Infiltration
7%
Murine Model
7%
Leading Causes of Death
7%
Syngeneic
7%
Ovarian Tissue
7%
Fluid Accumulation
7%
Ovarian Cancer Cells
7%
Neutralizing Antibodies
7%
Cell Processes
7%
Gynecologic Malignancies
7%
Increased Vascular Permeability
7%
Tissue Microarray
7%
Multiple Steps
7%
Prognostic Utility
7%
Pro-inflammatory Role
7%
Human Ovarian Cancer
7%
Metastatic Cascade
7%
Cancer Microenvironment
7%
Medicine and Dentistry
Urokinase Receptor
100%
Carcinosis
100%
Ovarian Cancer
53%
Neoplasm
15%
Implant
15%
Disease
7%
Cancer Cell
7%
In Vitro
7%
Recurrent Disease
7%
Biological Marker
7%
Debulking
7%
Krukenberg Tumor
7%
Macrophage
7%
Receptor
7%
Cancer
7%
Tumor Cell
7%
Survival Rate
7%
Catheter Ablation
7%
Solid Malignant Neoplasm
7%
Cancer Tissue
7%
Blood Vessel Permeability
7%
Neutralizing Antibody
7%
Tissue Microarray
7%
Peritoneal Fluid
7%
Pharmacology, Toxicology and Pharmaceutical Science
Urokinase Receptor
100%
Carcinomatosis
100%
Ovary Cancer
53%
Mouse
23%
Neoplasm
23%
Implant
15%
Disease
7%
Biological Marker
7%
Recurrent Disease
7%
Solid Malignant Neoplasm
7%
Receptor
7%
Ovary Carcinoma
7%
Survival Rate
7%
Neutralizing Antibody
7%